Abnormally expressed long noncoding RNA B3GALT5‐AS1 may serve as a biomarker for the diagnostic and prognostic of gastric cancer

Abstract

Early diagnosis of gastric cancer (GC) is an effective method to improve prognosis. Increasing number of long noncoding RNAs (lncRNAs) have been reported as biomarkers for several cancers. We aim to detect the level of lncRNA B3GALT5‐AS1 and its association with clinical parameters and to further explore its application value in GC. We measured serum B3GALT5‐AS1 expression in 107 patients with GC, 40 polyp patients, and 87 normal controls to explore the significance of serum B3GALT5‐AS1 in GC using the quantitative real‐time polymerase chain reaction method. The result demonstrated that B3GALT5‐AS1 level was markedly richer in GC patients than that in normal people (P < .001). B3GALT5‐AS1 may be served as a diagnostic marker for distinguishing GC patients from healthy people, and the proportion under the receiver operating characteristics curve is 0.816 (95% confidence interval, 0.758‐0.874; P = .03). Further exploration validated that high serum B3GALT5‐AS1 level was related to TNM stage (P = .024), and lymph node metastasis (P = .023). Our study suggested that serum B3GALT5‐AS1 may be employed as an ideal biomarker for early screening of GC.

A Novel Ferroptosis-Related Long Non-coding RNA Prognostic Risk Model for Gastric Cancer

“…It has been reported that the expression levels of lncRNAs AGAP2-AS1 and HOXA11-AS are signi cantly correlated with poorer prognosis and shorter OS in patients with GC, and lncRNA HOXA11-AS is tightly correlated with tumor size, TNM stage, and lymph node metastasis of GC (17,18). Previous studies have found that the expression levels of lncRNAs SNHG17 and B3GALT5-AS1 in GC tissues are signi cantly correlated with increased invasion depth, lymphatic metastasis, and advanced TNM stage (19,20). However, the expression of lncRNAs DGCR5 and ARHGAP27P1 are signi cantly downregulated in GC tissues, and its downregulation was closely associated with increased invasion depth, advanced TNM stage, and lymphatic metastasis (20,21).…”

Long non‑coding RNA B3GALT5‑AS1 contributes to the progression of gastric cancer via interacting with CSNK2A1

“…1A ). It has been previously suggested that B3GALT5-AS1 may originate from autocrine gastric tumor cells and is closely associated with gastric tumor metastasis ( 13 ). However, the specific regulatory mechanism underlying the effect of B3GALT5-AS1 on tumor metastasis remains unclear.…”

“…The moderate diagnostic value of CEA and CA199 for the early detection of gastric cancer highlights the importance and urgency of developing novel biomarkers with high specificity and sensitivity ( 30 ). It has been reported that B3GALT5-AS1 can acts as a diagnostic and prognostic biomarker of gastric cancer ( 13 ).…”

“…A study demonstrated that B3GALT5-AS1 expression was markedly increased in patients with gastric cancer compared with those with normal colonic epithelia ( 12 ). Moreover, high serum B3GALT5-AS1 levels were found to be associated with TNM stage and lymph node metastasis ( 13 ), suggesting a role of B3GALT5-AS1 in gastric cancer occurrence and progression. Another study suggested that serum levels of B3GALT5-AS1 could also serve as a diagnostic biomarker of colorectal cancer ( 14 ).…”

lncRNA DSCR8 mediates miR-137/Cdc42 to regulate gastric cancer cell proliferation, invasion, and cell cycle as a competitive endogenous RNA

“…An increasing number of studies have reported that lncRNAs have great potential value in the diagnosis and treatment of GC, such as lncRNA CADM1-AS1, 31 lncRNA p4516, 16 and B3GALT5-AS1. 32 lncRNAs RP11-169F17.1 and RP11-669N7.2 are found to be novel prognostic biomarkers of GC and might play an important role in gastric disorders caused by Helicobacter pylori infection, as revealed by the bioinformatics analysis of Yang and Song. 33 Additionally, KRT19P3 was found to inhibit the proliferation and metastasis of GC by COPS7A meditating the nuclear factor κB (NF-κB) pathway.…”